Skip to content

Cash & Equivalents at other companies

Eli Lilly logo
Eli LillyLLY
$5.28B+70.8%
AbbVie logo
AbbVieABBV
$9.39B+81.5%
Establishment Labs logo
Establishment LabsESTA
$68.1M-1.6%
Bausch Health Companies logo
Bausch Health CompaniesBHC
$1.31B+13.4%

Other financials

Income statement

See full
Revenue$39.4M0.0%
Gross profit$23.8M+1.6%
Operating income-$1.8M-13.4%
Net income-$2.4M+15.8%
EPS (diluted)-$0.03+40.0%

Balance sheet

See full
Total debt$71.0M-27.1%
Total equity$100.3M+31.5%
Total assets$192.0M-5.5%

Cash flow

See full
Operating cash flow$5.3M+507%
CapEx$51.0K-97.3%
Free cash flow$5.2M+605%

Valuation

See full
Market cap$311.81M+4.7%
Enterprise value$366.14M-6.0%
P/S2.1×+0.3×

Profitability

See full
Gross margin59.6%-0.3pp
Operating margin-7.8%-0.4pp
Net margin-11.3%-25.1pp
FCF margin-0.1%

Returns & leverage

See full
Return on equity-21.6%-78.3pp
Debt / equity0.7×-0.6×
Current ratio0.7×+0.2×

Where this comes from

Reported directly by AirSculpt Technologies, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: AirSculpt Technologies, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about AirSculpt Technologies, Inc.'s cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AirSculpt Technologies, Inc.'s cash & equivalents?
AirSculpt Technologies, Inc. (AIRS) reported cash & equivalents of $16.69M in Q1 2026.
How has AirSculpt Technologies, Inc.'s cash & equivalents changed year-over-year?
AirSculpt Technologies, Inc.'s cash & equivalents increased by 200.6% year-over-year, from $5.55M to $16.69M.
What is the long-term trend for AirSculpt Technologies, Inc.'s cash & equivalents?
Over 5 years (2020 to 2025), AirSculpt Technologies, Inc.'s cash & equivalents has grown at a -4.0% compound annual growth rate (CAGR), from $10.38M to $8.45M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.